

Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecule (Genetic Biomarkers, Protein Biomarkers, and Glyco-biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Others), and Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027

<https://marketpublishers.com/r/CC44EFF79B1EN.html>

Date: April 2020

Pages: 338

Price: US\$ 5,370.00 (Single User License)

ID: CC44EFF79B1EN

Abstracts

The global cancer biomarkers market was valued at \$10,944.08 million in 2019, and is projected to reach \$26,979.50 million by 2027, registering a CAGR of 11.8% from 2020 to 2027.

Cancer biomarkers are traceable substances or molecules that indicate the existence of cancerous cells in the body. The prevention of cancer by diagnosing and analyzing various cancer biomarkers using different diagnostic techniques is a profound approach to obtain rapid results for treatment. There are various types of biomarkers such as proteins, peptides, antibodies, and nucleic acids. Presence of these biomarkers in tissues, urine, serum, blood, and other body fluids indicate an abnormal process or a disease. Various such biomarkers for cancer indications have been studied and are being used for diagnostics, prognostics, personalized medicines, and surrogate endpoints. The identification of different types of biomarkers is an integral part of

various industries such as healthcare and pharmaceuticals.

The global cancer biomarkers market is expected to witness a significant growth during the forecast period due to increase in prevalence of various types of cancers such as breast, prostate, and lung cancer. In addition, surge in importance of biological & targeted drug therapies, technological advancements, accuracy, and reliability of cancer biomarkers also contribute toward the growth of the market. Moreover, increase in investments from governments and public & private sector toward R&D for cancer diagnostics have a positive impact on the market. However, high cost of drug development, threat of failure associated with cancer treatment, and unregulated government regulations and reimbursement policies hamper the market growth. In contrast, advancements of cancer research and significant unmet need for cancer diagnosis are anticipated to provide new opportunities for the cancer biomarkers market.

The market is segmented on the basis of profiling technology, biomolecule, cancer type, application, and region. By profiling technology, the market is bifurcated into omic technologies, imaging technologies, immunoassays, and cytogenetics-based tests. On the basis of biomolecules, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By biomolecule, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By cancer type, the market is segmented as breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others. Based on application, the market is segmented across diagnostics, drug discovery and development, prognostics, risk assessment, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.

Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.

Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Profiling Technology

Omic Technologies

Imaging Technologies

Immunoassays

Cytogenetics-based Tests

By Biomolecule

Genetic Biomarkers

Protein Biomarkers

Glyco-biomarkers

By Cancer Type

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Stomach Cancer

Others

By Application

Diagnostics

Drug Discovery and Development

Prognostics

Risk Assessment

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Russia

Rest of Europe

Asia Pacific

Japan

China

India

Australia

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

United Arab Emirates

Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Abbott Laboratories

Bio-Rad Laboratories, Inc.

Bristol-Myers Squibb Company

Exact Sciences Corporation

F.Hoffmann-La Roche Ltd.

Merck KGaA

PerkinElmer, Inc.

Qiagen N.V.

Siemens AG

Thermo Fisher Scientific, Inc.

Contents

CHAPTER 1:INTRODUCTION40

- 1.1.Report description40
- 1.2.Key benefits for stakeholders41
- 1.3.Key market segments43
 - 1.3.1.List of key players profiled in the report45
- 1.4.Research methodology46
 - 1.4.1.Secondary research48
 - 1.4.2.Primary research48
 - 1.4.3.Analyst tools and models49

CHAPTER 2:EXECUTIVE SUMMARY50

- 2.1.Key findings of the study52
- 2.2.CXO perspective53

CHAPTER 3:MARKET OVERVIEW54

- 3.1.Market definition and scope54
- 3.2.Biomarker Diagnosis vs. Conventional Diagnosis56
- 3.3.Key findings57
 - 3.3.1.Top investment pockets57
- 3.4.Porter's five forces analysis59
 - 3.4.1.Bargaining power of buyers59
 - 3.4.2.Bargaining power of suppliers60
 - 3.4.3.Threat of new entrants61
 - 3.4.4.Threat of substitutes62
 - 3.4.5.Intensity of competitive rivalry63
- 3.5.Top player positioning, 201964
- 3.6.Market dynamics65
 - 3.6.1.Drivers65
 - 3.6.1.1.Rise in incidence and prevalence of various cancer types65
 - 3.6.1.2.Growth in importance of biological and targeted drug therapies67
 - 3.6.1.3.Increase in acquisitions and collaborations69
 - 3.6.1.4.Increase in technological advancements70
 - 3.6.1.5.High accuracy and reliability70
 - 3.6.1.6.Rise in investment from government, public, and private sectors70

- 3.6.1.7. Increase in clinical trials71
- 3.6.1.8. Growth in popularity of personalized medicine and companion diagnostics71
- 3.6.2. Restraint72
 - 3.6.2.1. High cost of drug development and threat of failure72
 - 3.6.2.2. Unregulated government regulation and reimbursement policies72
 - 3.6.2.3. Adverse effects of cancer drug therapy73
- 3.6.3. Opportunity73
 - 3.6.3.1. Advancement of cancer drugs research73
 - 3.6.3.2. Increased focus towards advanced treatment protocols74
 - 3.6.3.3. Significant unmet need in cancer diagnosis74
 - 3.6.3.4. Increased awareness to reduce healthcare costs74
 - 3.6.3.5. Opportunities in emerging economies75
- 3.6.4. Impact Analyses75
- 3.7. PATENT ANALYSIS76
- 3.8. Clinical Trials Analysis78

CHAPTER 4: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY79

- 4.1. Overview79
 - 4.1.1. Market size and forecast, by profiling technologies80
- 4.2. OMIC TECHNOLOGIES82
 - 4.2.1. Key market trends and growth opportunities82
 - 4.2.2. Market size and forecast, by region83
 - 4.2.3. Market analysis, by country84
 - 4.2.4. Market size and forecast, by type85
 - 4.2.5. Genomics86
 - 4.2.5.1. Market Size and forecast87
 - 4.2.5.2. Next Generation Sequencing (NGS)88
 - 4.2.5.3. Microarray89
 - 4.2.5.4. Polymerase chain reaction (PCR)89
 - 4.2.6. Proteomics90
 - 4.2.6.1. Market size and forecast90
 - 4.2.6.2. Mass spectrometry92
 - 4.2.6.3. 2D gel electrophoresis92
 - 4.2.6.4. Protein microarray technology93
 - 4.2.6.5. Antibody array technology94
 - 4.2.6.6. Peptide array technology94
 - 4.2.7. Other omic technologies95
 - 4.2.7.1. Market size and forecast95

- 4.2.7.2. Metabolomics96
- 4.2.7.3. Glycomics97
- 4.3. IMAGING TECHNOLOGIES97
 - 4.3.1. Key market trends and growth opportunities97
 - 4.3.2. Market size and forecast, by region98
 - 4.3.3. Market analysis, by countries99
 - 4.3.4. Market size and forecast, by type100
 - 4.3.5. Magnetic resonance imaging (MRI)101
 - 4.3.5.1. Market size and forecast102
 - 4.3.6. Positron emission tomography (PET)103
 - 4.3.6.1. Market size and forecast103
 - 4.3.7. Computed tomography (CT)104
 - 4.3.7.1. Market size and forecast105
 - 4.3.8. Mammography105
 - 4.3.8.1. Market size and forecast106
 - 4.3.9. Ultrasound107
 - 4.3.9.1. Market size and forecast107
- 4.4. IMMUNOASSAYS108
 - 4.4.1. Key market trends and growth opportunities109
 - 4.4.2. Market size and forecast, by region109
 - 4.4.3. Market analysis, by country110
 - 4.4.4. Market size and forecast, by type112
 - 4.4.5. Immunohistochemistry (IHC) tests113
 - 4.4.5.1. Market size and forecast113
 - 4.4.6. Enzyme-linked immunosorbent assay (ELISA)114
 - 4.4.6.1. Market size and forecast114
 - 4.4.7. Flow cytometry115
 - 4.4.7.1. Market size and forecast116
- 4.5. CYTOGENETICS-BASED TESTS117
 - 4.5.1. Key market trends and growth opportunities117
 - 4.5.2. Market size and forecast, by region118
 - 4.5.3. Market analysis, by country119
 - 4.5.4. Market size and forecast, by type120
 - 4.5.5. In-situ hybridization121
 - 4.5.5.1. Market size and forecast121
 - 4.5.6. Others122
 - 4.5.6.1. Market size and forecast122

CHAPTER 5: CANCER BIOMARKERS MARKET, BY BIOMOLECULE124

5.1.Overview124

5.1.1.Market size and forecast125

5.2.Genetic Biomarkers126

5.2.1.Market size and forecast, by region128

5.2.2.Market analysis, by country129

5.3.Protein Biomarkers130

5.3.1.Market size and forecast, by region130

5.3.2.Market analysis, by country131

5.4.Glyco-Biomarkers133

5.4.1.Market size and forecast, by region134

5.4.2.Market analysis, by country135@CHAPTER 6:CANCER BIOSENSORS

MARKET, BY CANCER TYPE136**6.1.Overview136**

6.1.1.Market size and forecast137

6.2.Breast Cancer138

6.2.1.Market size and forecast, by region139

6.2.2.Market analysis, by country140

6.3.Lung Cancer141

6.3.1.Market size and forecast, by region141

6.3.2.Market analysis, by country142

6.4.Colorectal cancer143

6.4.1.Market size and forecast, by region144

6.4.2.Market analysis, by country145

6.5.Prostate cancer146

6.5.1.Market size and forecast, by region147

6.5.2.Market analysis, by country148

6.6.Stomach cancer149

6.6.1.Market size and forecast, by region150

6.6.2.Market analysis, by country150

6.7.Others152

6.7.1.Market size and forecast, by region152

6.7.2.Market analysis, by country153

CHAPTER 7:CANCER BIOMARKER MARKET, BY APPLICATION155**7.1.Overview155**

7.1.1.Market size and forecast155

7.2.Diagnostics157

- 7.2.1. Market size and forecast, by region 158
- 7.2.2. Market analysis, by country 159
- 7.3. Drug Discovery and Development 160
 - 7.3.1. Market size and forecast, by region 161
 - 7.3.2. Market analysis, by country 162
- 7.4. Prognostics 163
 - 7.4.1. Market size and forecast, by region 164
 - 7.4.2. Market analysis, by country 164
- 7.5. Risk Assessment 166
 - 7.5.1. Market size and forecast, by region 166
 - 7.5.2. Market analysis, by country 167
- 7.6. Others 168
 - 7.6.1. Market size and forecast, by region 169
 - 7.6.2. Market analysis, by country 170

CHAPTER 8: CANCER BIOMARKERS MARKET, BY REGION 172

- 8.1. Overview 172
 - 8.1.1. Market size and forecast 173
- 8.2. North America 174
 - 8.2.1. Key market trends and opportunities 174
 - 8.2.2. Market analysis by country 175
 - 8.2.2.1. U.S. 176
 - 8.2.2.1.1. U.S. market size and forecast, by profiling technologies 176
 - 8.2.2.1.2. U.S. market size and forecast, by biomolecules 177
 - 8.2.2.1.3. U.S. market size and forecast, by cancer type 178
 - 8.2.2.1.4. U.S. market size and forecast, by application 179
 - 8.2.2.2. Canada 180
 - 8.2.2.2.1. Canada market size and forecast, by profiling technologies 180
 - 8.2.2.2.2. Canada market size and forecast, by biomolecules 182
 - 8.2.2.2.3. Canada market size and forecast, by cancer type 183
 - 8.2.2.2.4. Canada market size and forecast, by application 184
 - 8.2.2.3. Mexico 185
 - 8.2.2.3.1. Mexico market size and forecast, by profiling technologies 185
 - 8.2.2.3.2. Mexico market size and forecast, by biomolecules 187
 - 8.2.2.3.3. Mexico market size and forecast, by cancer type 188
 - 8.2.2.3.4. Mexico market size and forecast, by application 189
 - 8.2.3. North America market size and forecast, by profiling technologies 190
 - 8.2.4. North America market size and forecast, by biomolecules 191

8.2.5.	North America market size and forecast, by cancer type	192
8.2.6.	North America market size and forecast, by application	193
8.3.	Europe	194
8.3.1.	Key market trends and opportunities	194
8.3.2.	Market analysis by country	195
8.3.2.1.	Germany	197
8.3.2.1.1.	Germany market size and forecast, by profiling technologies	197
8.3.2.1.2.	Germany market size and forecast, by biomolecules	199
8.3.2.1.3.	Germany market size and forecast, by cancer type	200
8.3.2.1.4.	Germany market size and forecast, by application	201
8.3.2.2.	France	202
8.3.2.2.1.	France market size and forecast, by profiling technologies	202
8.3.2.2.2.	France market size and forecast, by biomolecules	204
8.3.2.2.3.	France market size and forecast, by cancer type	205
8.3.2.2.4.	France market size and forecast, by application	206
8.3.2.3.	UK	207
8.3.2.3.1.	UK market size and forecast, by profiling technologies	207
8.3.2.3.2.	UK market size and forecast, by biomolecules	208
8.3.2.3.3.	UK market size and forecast, by cancer type	209
8.3.2.3.4.	UK market size and forecast, by application	210
8.3.2.4.	Italy	211
8.3.2.4.1.	Italy market size and forecast, by profiling technologies	211
8.3.2.4.2.	Italy market size and forecast, by biomolecules	212
8.3.2.4.3.	Italy market size and forecast, by cancer type	213
8.3.2.4.4.	Italy market size and forecast, by application	214
8.3.2.5.	Russia	215
8.3.2.5.1.	Russia market size and forecast, by profiling technologies	215
8.3.2.5.2.	Russia market size and forecast, by biomolecules	217
8.3.2.5.3.	Russia market size and forecast, by cancer type	218
8.3.2.5.4.	Russia market size and forecast, by application	219
8.3.2.6.	Rest of Europe	220
8.3.2.6.1.	Rest of Europe market size and forecast, by profiling technologies	220
8.3.2.6.2.	Rest of Europe market size and forecast, by biomolecules	222
8.3.2.6.3.	Rest of Europe market size and forecast, by cancer type	223
8.3.2.6.4.	Rest of Europe market size and forecast, by application	224
8.3.3.	Europe market size and forecast, by profiling technologies	225
8.3.4.	Europe market size and forecast, by biomolecules	226
8.3.5.	Europe market size and forecast, by cancer type	227
8.3.6.	Europe market size and forecast, by application	228

8.4.Asia-Pacific	229
8.4.1.Key market trends and opportunities	229
8.4.2.Market analysis by country	230
8.4.2.1.Japan	231
8.4.2.1.1.Japan market size and forecast, by profiling technologies	231
8.4.2.1.2.Japan market size and forecast, by biomolecules	233
8.4.2.1.3.Japan market size and forecast, by cancer type	234
8.4.2.1.4.Japan market size and forecast, by application	235
8.4.2.2.China	236
8.4.2.2.1.China market size and forecast, by profiling technologies	236
8.4.2.2.2.China market size and forecast, by biomolecules	237
8.4.2.2.3.China market size and forecast, by cancer type	238
8.4.2.2.4.China market size and forecast, by application	239
8.4.2.3.Australia	240
8.4.2.3.1.Australia market size and forecast, by profiling technologies	240
8.4.2.3.2.Australia market size and forecast, by biomolecules	242
8.4.2.3.3.Australia market size and forecast, by cancer type	243
8.4.2.3.4.Australia market size and forecast, by application	244
8.4.2.4.India	245
8.4.2.4.1.India market size and forecast, by profiling technologies	245
8.4.2.4.2.India market size and forecast, by biomolecules	246
8.4.2.4.3.India market size and forecast, by cancer type	247
8.4.2.4.4.India market size and forecast, by application	248
8.4.2.5.Rest of Asia-Pacific	249
8.4.2.5.1.Rest of Asia-Pacific market size and forecast, by profiling technologies	249
8.4.2.5.2.Rest of Asia-Pacific market size and forecast, by biomolecules	250
8.4.2.5.3.Rest of Asia-Pacific market size and forecast, by cancer type	251
8.4.2.5.4.Rest of Asia-Pacific market size and forecast, by application	252
8.4.3.Asia-Pacific market size and forecast, by profiling technologies	253
8.4.4.Asia-Pacific market size and forecast, by biomolecules	254
8.4.5.Asia-Pacific market size and forecast, by cancer type	255
8.4.6.Asia-Pacific market size and forecast, by application	256
8.5.LAMEA	257
8.5.1.Key market trends and opportunities	257
8.5.2.Market analysis by country	258
8.5.2.1.Brazil	260
8.5.2.1.1.Brazil market size and forecast, by profiling technologies	260
8.5.2.1.2.Brazil market size and forecast, by biomolecules	261
8.5.2.1.3.Brazil market size and forecast, by cancer type	262

- 8.5.2.1.4. Brazil market size and forecast, by application 263
- 8.5.2.2. Saudi Arabia 264
 - 8.5.2.2.1. Saudi Arabia market size and forecast, by profiling technologies 264
 - 8.5.2.2.2. Saudi Arabia market size and forecast, by biomolecules 266
 - 8.5.2.2.3. Saudi Arabia market size and forecast, by cancer type 267
 - 8.5.2.2.4. Saudi Arabia market size and forecast, by application 268
- 8.5.2.3. United Arab Emirates 269
 - 8.5.2.3.1. United Arab Emirates market size and forecast, by profiling technologies 269
 - 8.5.2.3.2. United Arab Emirates market size and forecast, by biomolecules 270
 - 8.5.2.3.3. United Arab Emirates market size and forecast, by cancer type 271
 - 8.5.2.3.4. United Arab Emirates market size and forecast, by application 272
- 8.5.2.4. Rest of LAMEA 273
 - 8.5.2.4.1. Rest of LAMEA market size and forecast, by profiling technologies 273
 - 8.5.2.4.2. Rest of LAMEA market size and forecast, by biomolecules 275
 - 8.5.2.4.3. Rest of LAMEA market size and forecast, by cancer type 276
 - 8.5.2.4.4. Rest of LAMEA market size and forecast, by application 277
- 8.5.3. LAMEA market size and forecast, by profiling technologies 278
- 8.5.4. LAMEA market size and forecast, by biomolecules 279
- 8.5.5. LAMEA market size and forecast, by cancer type 280
- 8.5.6. LAMEA market size and forecast, by application 281

CHAPTER 9: COMPANY PROFILES 282

- 9.1. Abbott Laboratories 282
 - 9.1.1. Company overview 282
 - 9.1.2. Company snapshot 282
 - 9.1.3. Operating business segments 283
 - 9.1.4. Product portfolio 283
 - 9.1.5. Business performance 285
- 9.2. BIO-RAD LABORATORIES, INC. 287
 - 9.2.1. Company overview 287
 - 9.2.2. Company snapshot 288
 - 9.2.3. Operating business segments 289
 - 9.2.4. Product Portfolio 289
 - 9.2.5. Business performance 290
- 9.3. Bristol-Myers Squibb Company 292
 - 9.3.1. Company overview 292
 - 9.3.2. Company snapshot 293

- 9.3.3.Operating business segments293
- 9.3.4.Product portfolio294
- 9.3.5.Business performance294
- 9.3.6.Key strategic moves and developments296
- 9.5.EXACT SCIENCES CORPORATION297
 - 9.5.1.Company overview297
 - 9.5.2.Company snapshot297
 - 9.5.3.Operating business segments298
 - 9.5.4.Product portfolio298
 - 9.5.5.Business performance299
 - 9.5.6.Key strategic moves and developments299
- 9.6.F. HOFFMANN-LA ROCHE LTD.301
 - 9.6.1.Company overview301
 - 9.6.2.Company snapshot301
 - 9.6.3.Operating business segments302
 - 9.6.4.Product portfolio303
 - 9.6.5.Business performance304
 - 305
 - 9.6.6.Key strategic moves and developments306
- 9.7.Merck KGaA307
 - 9.7.1.Company overview307
 - 9.7.2.Company snapshot307
 - 9.7.3.Operating business segments308
 - 9.7.4.Product portfolio308
 - 9.7.5.Business performance309
 - 9.7.6.Key strategic moves and developments311
- 9.8.PERKINELMER, INC.312
 - 9.8.1.Company overview312
 - 9.8.2.Company snapshot312
 - 9.8.3.Operating business segments313
 - 9.8.4.Product portfolio314
 - 9.8.5.Business performance315
 - 9.8.6.Key strategic moves and developments317
- 9.9.QIAGEN N.V.318
 - 9.9.1.Company overview318
 - 9.9.2.Company snapshot318
 - 9.9.3.Operating business segments319
 - 9.9.4.Product portfolio320
 - 9.9.5.Business performance320

- 9.9.6.Key strategic moves and developments322
- 9.10.Siemens AG323
 - 9.10.1.Company overview323
 - 9.10.2.Company snapshot324
 - 9.10.3.Operating business segments324
 - 9.10.4.Product portfolio325
 - 9.10.5.Business performance326
- 9.11.THERMO FISHER SCIENTIFIC, INC.328
 - 9.11.1.Company overview328
 - 9.11.2.Company snapshot328
 - 9.11.3.Operating business segments329
 - 9.11.4.Product portfolio331
 - 9.11.5.Business performance332
 - 9.11.6.Key strategic moves and developments334

List Of Tables

LIST OF TABLES

TABLE 01.CONVENTIONAL DIAGNOSTICS VS. DIAGNOSTIC BIOMARKER TECHNIQUES60

TABLE 02.GLOBAL CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGIES, 2019–2027 (\$MILLION)86

TABLE 03.OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)89

TABLE 04.OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 (\$MILLION)92

TABLE 05.GENOMICS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 (\$MILLION)93

TABLE 06.PROTEOMICS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 (\$MILLION)97

TABLE 07.OTHER OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 (\$MILLION)101

TABLE 08.IMAGING TECHNOLOGIES CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)105

TABLE 09.IMAGING TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 (\$MILLION)107

TABLE 10.IMMUNOASSAYS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)116

TABLE 11.IMMUNOASSAYS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 (\$MILLION)118

TABLE 12.CYTOGENETICS-BASED TESTS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)124

TABLE 13.CYTOGENETICS-BASED TESTS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)127

TABLE 14.GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE, BY BIOMOLECULE, 2019–2027 (\$MILLION)131

TABLE 15.GENETIC BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)134

TABLE 16.PROTEIN BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)137

TABLE 17.GLYCO-BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)140

TABLE 18.GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE,

2019–2027 (\$MILLION)144

TABLE 19.BREAST CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)146

TABLE 20.LUNG CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)149

TABLE 21.COLORECTAL CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)151

TABLE 22.PROSTATE CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)154

TABLE 23.STOMACH CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)157

TABLE 24.OTHERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)160

TABLE 25.GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION, 2019–2027 (\$MILLION)163

TABLE 26.DIAGNOSTICS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)165

TABLE 27.DRUG DISCOVERY AND DEVELOPMENT CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)169

TABLE 28.PROGNOSTICS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)171

TABLE 29.RISK ASSESSMENT CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)174

TABLE 30.OTHERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 (\$MILLION)177

TABLE 31.CANCER BIOMARKERS MARKET, BY REGION, 2018-2026 (\$MILLION)180

TABLE 32.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 (\$MILLION)182

TABLE 33.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)183

TABLE 34.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)185

TABLE 35.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)186

TABLE 36.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)187

TABLE 37.CANADA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)188

TABLE 38.CANADA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)190

TABLE 39.CANADA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)191

TABLE 40.CANADA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)192

TABLE 41.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)193

TABLE 42.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)194

TABLE 43.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)195

TABLE 44.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)196

TABLE 45.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)197

TABLE 46.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)198

TABLE 47.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)199

TABLE 48.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)200

TABLE 49.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 (\$MILLION)202

TABLE 50.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)204

TABLE 51.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)206

TABLE 52.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)207

TABLE 53.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)208

TABLE 54.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)209

TABLE 55.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)210

TABLE 56.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)211

TABLE 57.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION

2019–2027 (\$MILLION)212

TABLE 58.UK CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)213

TABLE 59.UK CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)214

TABLE 60.UK CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)215

TABLE 61.UK CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)216

TABLE 62.ITALY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)217

TABLE 63.ITALY CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)218

TABLE 64.ITALY CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)219

TABLE 65.ITALY CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)220

TABLE 66.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)221

TABLE 67.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)222

TABLE 68.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)223

TABLE 69.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)224

TABLE 70.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)225

TABLE 71.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)226

TABLE 72.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)227

TABLE 73.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)228

TABLE 74.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)229

TABLE 75.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)230

TABLE 76.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)231

- TABLE 77.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)232
- TABLE 78.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 (\$MILLION)235
- TABLE 79.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)236
- TABLE 80.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)237
- TABLE 81.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)238
- TABLE 82.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)239
- TABLE 83.CHINA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)240
- TABLE 84.CHINA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)241
- TABLE 85.CHINA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)242
- TABLE 86.CHINA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)243
- TABLE 87.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)244
- TABLE 88.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)245
- TABLE 89.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)246
- TABLE 90.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)247
- TABLE 91.INDIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)248
- TABLE 92.INDIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)249
- TABLE 93.INDIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)250
- TABLE 94.INDIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)251
- TABLE 95.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)252
- TABLE 96.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY

BIOMOLECULES 2019–2027 (\$MILLION)253

TABLE 97.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)254

TABLE 98.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)255

TABLE 99.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)256

TABLE 100.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)257

TABLE 101.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)258

TABLE 102.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)259

TABLE 103.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 (\$MILLION)261

TABLE 104.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)263

TABLE 105.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)264

TABLE 106.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)265

TABLE 107.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)266

TABLE 108.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)267

TABLE 109.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)269

TABLE 110.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)270

TABLE 111.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)271

TABLE 112.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)272

TABLE 113.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)273

TABLE 114.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)274

TABLE 115.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)275

TABLE 116.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)276

TABLE 117.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)278

TABLE 118.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)279

TABLE 119.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)280

TABLE 120.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 (\$MILLION)281

TABLE 121.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 (\$MILLION)282

TABLE 122.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 (\$MILLION)283

TABLE 123.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 (\$MILLION)284

TABLE 124.ABBOTT: COMPANY SNAPSHOT285

TABLE 125.ABBOTT: OPERATING SEGMENTS286

TABLE 126.ABBOTT: PRODUCT PORTFOLIO287

TABLE 127.BIO-RAD: COMPANY SNAPSHOT291

TABLE 128.BIO-RAD: OPERATING SEGMENTS292

TABLE 129.BIO-RAD: PRODUCT PORTFOLIO292

TABLE 130.BMS: COMPANY SNAPSHOT296

TABLE 131.BMS: PRODUCT PORTFOLIO297

TABLE 132.EXACT SCIENCES: COMPANY SNAPSHOT300

TABLE 133.EXACT SCIEN

I would like to order

Product name: Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecule (Genetic Biomarkers, Protein Biomarkers, and Glyco-biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Others), and Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027

Product link: <https://marketpublishers.com/r/CC44EFF79B1EN.html>

Price: US\$ 5,370.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC44EFF79B1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970